Depakote ER in Bipolar Depression

NCT ID: NCT00186186

Last Updated: 2017-04-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-01-31
• Study Completion Date: 2009-01-31

Brief Summary

The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.

Detailed Description

Mood disorders are important public health problems. Bipolar disorder is a major psychiatric disorder characterized by mood cycles alternating between mania and depression and affects approximately 1% of the population. Most patients are treated beginning in the early twenties and then embark on a course marked by multiple recurrences, hospitalizations, and encounters with legal authorities. These disorders inflict substantial morbidity which yields important deficits in occupational and interpersonal function. The risk of suicide in mood disorders may be as high as 10%.

Although the outlook for recovery from acute manic or depressive episodes is generally excellent, the long-term prognosis of the disorder varies tremendously across the patient population. The introduction of lithium, anticonvulsants and atypical antipsychotics significantly changes the outlook for bipolar disorder, with some individuals on chronic treatment attaining complete remission and indefinite prophylaxis against mood episodes. However, such optimum outcomes may be limited to as few as one-third to one-half of all treated patients. The remaining experiences various combinations of breakthrough mood episodes, including chronic mood instability, persistent depression, and rapid cycling.

Very little research has been conducted with bipolar disorder, and no medications have an FDA indication to treat bipolar depression. Previous studies suggest that Depakote is promising in the treatment of mixed and depressed episodes of bipolar disorder. This study utilizes the extended release formulation of divalproex sodium, with demonstrated increased tolerability.

We propose investigating safety, tolerability and efficacy of Depakote ER monotherapy in Bipolar I, II or NOS depression, and monitoring associated changes in brain GABA levels. In addition, we intend to evaluate and assess the differences between brain metabolic rate and GABA levels in bipolar disorder patients and healthy volunteers.

Conditions

Depression, Bipolar

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Depakote ER

Depakote ER up to 1500 mg/day

Group Type: EXPERIMENTAL

Depakote ER

Intervention Type: DRUG

Depakote ER

Interventions

Depakote ER

Depakote ER

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Bipolar I, II or NOS currently suffering from depression
• Both: both female and male participants are being studied
• Adults 18 years and older of any race

Exclusion Criteria

• Schizophrenia or schizoaffective disorder and other disorders excluded at the discretion of the investigator's discretion
• Substance dependence within the past 3 months and abuse within the past 2 weeks prior to study.
• Positive screen for psychoactive drugs, stimulants or drugs of abuse (excluding marijuana, as long as dependence and abuse are ruled out according to DSM-IV)
• Significant risk harm to self or others based on history and mental status exam
• Clinically significant or unstable medical condition
• Unstable thyroid pathology and treatment initiated or altered within the past 3 months
• Clinically significant abnormal laboratory test results, vital signs, as judged by the investigators
• Women pregnant or nursing, or WOCBP who do not use adequate contraception or who are judged to be unreliable in their use of contraception
• Subjects who failed (because of inefficacy or adverse effects) an adequate trial of Depakote; eligible patient's may not have received Depakote within 30 days of screen

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott

INDUSTRY

Sponsor Role: collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

Sponsor Role: collaborator

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Terrence Ketter

Professot

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Terence A. Ketter, MD

Role: STUDY_DIRECTOR

Stanford University, Department of Psychiatry and Behavioral Sciences

Locations

Stanford University Bipolar Disorders Clinic

Stanford, California, United States

Countries

United States

References

Wang PW, Nowakowska C, Chandler RA, Hill SJ, Nam JY, Culver JL, Keller KL, Ketter TA. Divalproex extended-release in acute bipolar II depression. J Affect Disord. 2010 Jul;124(1-2):170-3. doi: 10.1016/j.jad.2009.10.021.

Reference Type: RESULT

PMID: 19923006 (View on PubMed)

Other Identifiers

79130

Identifier Type: -

Identifier Source: org_study_id